(MedPage Today) -- The FDA granted accelerated approval to the first cereblon E3 ligase modulation (CELMoD) therapy for relapsed or refractory multiple myeloma, the agency announced on Thursday. An oral drug, iberdomide (Zenbexus) is approved...